5
Feb
2018
The Caveman’s Guide to Productivity
One TR subscriber already knew about some of my quirks: he and I rode in a van together for 26 hours straight to do the 200-mile Ragnar Reach the Beach Relay in New Hampshire. But when I published last month’s column detailing my Everest training, he wanted to know more. “I study performance pretty carefully, so all these kinds of questions fascinate...Read More 
Share:
29
Jan
2018
The Boston Cancer Summit & Seattle Cancer Summit. Two Can’t-Miss Events
Cancer wasn’t that exciting to write about when I started 15 years ago. It is now. Survival rates for several forms of cancer are going in the right direction. Immunotherapy, targeted therapy, new information on genes and proteins that redefine the molecular nature of malignancy? It’s coming together. The science is bursting with creativity, and moving fast. I’m thinking and...Read More
Share:
22
Jan
2018
Lessons in Digging Deep (January Update: Everest Climb to Fight Cancer at Fred Hutch)
Many of you have a big dream. Many of you have your own “Everest” – a big, hairy audacious goal that will take serious time and sacrifice to achieve. I deeply admire those of you doing your best to move the needle for human health, whether it’s for cancer or some other serious illness. When the going gets tough, you...Read More
Share:
20
Nov
2017
How Will the Great Sex Predator Purge Alter Gender Dynamics at Work?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
13
Nov
2017
The Oxygen-Providing, High-Autonomy M&A Model: A Sign of Things to Come
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
6
Nov
2017
The Dark Underbelly of Startup Fundraising: Working Through Self-Doubt, Loneliness
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
30
Oct
2017
Atlas, Amgen, Lilly Bet $30M for Kymera’s Imaginative Protein Degradation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
16
Oct
2017
Exclusive: Illumina Ventures Rakes in $230M Fund, Declares Independence from Parent, Mostly
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
9
Oct
2017
Where Does Alzheimer’s R&D Go Now? Plenty of Directions
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
25
Sep
2017
Socializing After Hours: It’s How Biotech Runs, and Should Be Open to All
Back in the “Mad Men” era, there was the three-martini lunch. When boozy mid-day breaks went out of style, business executives found other ways to grease the wheels of social interaction outside of the office. Like doing deals on the golf course. There are many ways to cultivate the social connections that are a crucial step toward forming trusting relationships...Read More
Share:
18
Sep
2017
After the Boom: How’s It Going for Big Pharma Vets At Startups?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
11
Sep
2017
Corporate VCs: How Do They Get Rewarded? How Should They Be Rewarded?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
31
Aug
2017
How Gilead Can Play to Win in CAR-T Over the Next Decade
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
21
Aug
2017
Scott Gottlieb’s First 100 Days at the FDA: A Timeline
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
14
Aug
2017
How Do You Manage Biotech Information to Think Widely and Deeply?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
10
Jul
2017
Allergan’s Social Contract, One Year Later: CEO Brent Saunders Reflects on the Expected and Unexpected
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
26
Jun
2017
Watershed Moments: When Celgene and Bristol-Myers Squibb Became Deal Winners
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
19
Jun
2017
An American Sickness: A Skillful Deconvolution of the U.S. Healthcare Mess
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
12
Jun
2017
Long-Distance Relationships in Biotech Startups: How to Make Them Work
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
25
May
2017
12 VCs Who Matter, But You Never Read About
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: